Skip to content

Misoprostol Before Elective Caesarean Section for Decreasing the Neonatal Respiratory Morbidity

Misoprostol Before Elective Caesarean Section for Decreasing the Neonatal Respiratory Morbidity: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03031353
Enrollment
170
Registered
2017-01-25
Start date
2017-01-31
Completion date
2018-06-30
Last updated
2018-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Delivery Affecting Fetus, Transient Tachypnea Newborn

Brief summary

Neonatal respiratory distress may occur in either term or preterm newborns with a higher relative risk in preterm, and whether born vaginally or through caesarean section, but in a higher percentage after elective caesarean section whose rate is rising. Prostaglandins may be given about one hour before an elective caesarean section after excluding the presence of contraindication to their use to decrease the neonatal respiratory diseases and thus, the number of children who suffered from bronchopulmonary dysplasia that occurs frequently in children who had previously TTN will diminish.

Interventions

DRUGMisoprostol

Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage

DRUGPlacebos

placebos tablet will be given before elective Cesarean sections

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Age: 18 years or more. * Term singleton pregnancy (38 - 38+6 weeks gestation). * Planned for elective transverse lower segment caesarean section with an indication.

Exclusion criteria

* Women with history of significant cardiac disease, eclampsia, pre eclampsia, epilepsy, severe asthma, severe allergic condition, vascular disease, renal or hepatic disease. * Women with contraindication to prostaglandins as Glucoma or known hypersensitivity to prostaglandins or specifically for misoprostol. * Psychological problem or mental disease that renders the patient not able to understand the nature, scope, and sequences of the study. * Pregnancies with known foetal malformation/s or chromosomal aberration.

Design outcomes

Primary

MeasureTime frameDescription
The need for admission to neonatal intensive care unit (NICU)first 24 hours after deliveryNumber of newborns admitted to NICU for respiratory morbidity

Secondary

MeasureTime frameDescription
APGAR score below 6 at 5 minute5 minutes after deliverynumber of newborns delivered with APGAR score below 6 at 5 minutes

Other

MeasureTime frameDescription
neonatal mortalityfirst month after deliverynumber of neonates died from respiratory morbidity with one month of delivery

Countries

Egypt

Contacts

Primary ContactAhmed M kotb, MD
ahmedmkotp@hotmail.com01008681999
Backup Contactahmed DR kotb, MD
ahmedmkotp@hotmail.com1008681999

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026